Industry News

• Apricus Biosciences announces proposed public offering of common stock and warrants  Apricus Biosciences announced it intends to offer shares of common stock and warrants in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock and warrants to cover over-allotments.
  May 22, 2013  
• Taming suspect gene reverses schizophrenia-like abnormalities in mice  Scientists have reversed behavioral and brain abnormalities in adult mice that resemble some features of schizophrenia by restoring normal expression to a suspect gene that is over-expressed in humans with the illness.
  May 22, 2013  
• Mega genomes of spruce species decoded  Canadian and Swedish scientists released genome sequences of two of the most economically important trees in the world. At 20-30 billion base-pairs and up to 10 times larger than the human genome, the white spruce genome and Norway spruce genome are the largest genome sequence assemblies to date.
  May 22, 2013  
• NIH researchers conduct first genomic survey of human skin fungal diversity  In the first study of human fungal skin diversity, NIH researchers sequenced the DNA of fungi at skin sites of healthy adults to define the normal populations across the skin and to provide a framework for investigating fungal skin conditions.
  May 22, 2013  
• Boston Scientific Promus drug-eluting stent systems provide safety and efficacy data  Boston Scientific reports positive results from two trials evaluating new, innovative drug-eluting stent technologies, which are emerging treatment options for coronary heart disease.
  May 22, 2013  
• Doctors and hospitals' use of health IT more than doubles since 2012  HHS announced more than half of all doctors and other eligible providers have received Medicare or Medicaid incentive payments for adopting electronic health records. HHS has exceeded its goal for 50 percent of doctor offices and 80 percent of eligible hospitals to have EHRs by the end of 2013.
  May 22, 2013  
• Covidien announces clinical trial data showing benefits of endoscopic ablation therapy  Covidien announced results from a prospective, multicenter, randomized, controlled clinical trial show that endoscopic ablation therapy using the Barrx™ RF Ablation System is effective at eliminating Barrett’s esophagus, a pre-cancerous condition of the esophagus, and preventing disease progression.
  May 22, 2013  
• Oncolytics meets primary endpoint for first stage of phase 2 metastatic melanoma trial  Oncolytics announced preliminary results from its Phase 2 clinical trial in patients with metastatic melanoma using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel. The primary objective of the trial is to assess the antitumour effect of the treatment regimen.
  May 22, 2013  
• Boston Scientific reports LotusTM valve system met primary performance endpoint in trial  Boston Scientific reports positive results from a pre-specified analysis of the first 60 patients enrolled in the REPRISE II trial evaluating performance and safety of the Lotus™ Valve System in symptomatic patients with severe aortic valve disease considered at high risk for valve replacement.
  May 22, 2013  
• Discoveries could change shape of battle against viruses   Researchers at the University of Alberta have discovered a new drug target, developed a new drug and identified a new way to design drugs—all of which could be a winning combination in the battle against viruses. The findings were published in the Journal of Virology.
  May 22, 2013  

   (next 10 articles)